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Abstract 
 
Objective: To estimate the Minimum Clinically Important Improvement (MCII) and Patient 
Acceptable Symptomatic State (PASS) values for 4 generic outcomes in 5 rheumatic diseases 
and 7 countries.  
Methods: We conducted a multinational (Australia, France, Italy, Lebanon, Morocco, Spain, 
The Netherlands), 4-week cohort study involving 1,532 patients which were prescribed 
NSAISDs for ankylosing spondylitis, chronic back pain, hand osteoarthritis, hip and/or knee 
osteoarthritis or rheumatoid arthritis. The MCII and PASS values were estimated with the 75
th
 
percentile approach for 4 generic outcomes: pain, patient global assessment, functional 
disability and physician global assessment, all normalized to a 0-100 score. 
Results: For the whole sample, the estimated MCII values for absolute change at 4 weeks 
(95% confidence interval [95% CI]) were -17 (-18, -15) for pain; -15 (-16, -14) for patient 
global assessment; -12 (-13, -11) for functional disability assessment; and -14 (-15, -14) for 
physician global assessment. For the whole sample, the estimated PASS values were 42 (40, 
44) for pain; 43 (41, 45) for patient global assessment; 43 (41, 44) for functional disability 
assessment; and 39 (37, 40) for physician global assessment. Estimates were consistent across 
diseases and countries (for subgroups ≥20 patients). 
Conclusion: This work allows for promoting the use of values of MCII (15/100 for absolute 
improvement, 20% for relative improvement) and PASS (40/100) in reporting the results of 
trials of any of the 5 involved rheumatic diseases with pain, patient global assessment, 
physical function or physician global assessment used as outcome criteria. 
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Significance and Innovations  
 
 Defining a minimal important improvement or an acceptable state to use in reporting the 
results of trials or cohorts is widely considered important.  
 
 This article reports the minimal clinically important improvement (MCII) and the patient 
acceptable symptomatic state (PASS) values estimated for the first time for 4 generic 
outcomes in 5 chronic rheumatic diseases – rheumatic arthritis, ankylosing spondyitis, 
hand osteoarthritis, hip and/or knee osteoarthritis and chronic back pain -- and 7 countries 
in the same cohort study. 
 
 The estimates of the MCII and PASS were similar across diseases and countries, whatever 
the outcome measure. This consistency reinforces the robustness of these concepts and 
allows for promoting the use of values of MCII (15/100 for absolute improvement, 20% 
for relative improvement) and PASS (40/100) when reporting the results of trials of the 5 
involved rheumatic diseases with pain, patient global assessment, physical function or 
physician global assessment used as outcome criteria.  
 5 
Introduction 
The choice of an outcome measure is a major step in the design of clinical trials. Trials of 
rheumatology ideally should systematically evaluate pain, functional impairment, and patient 
global assessment. For most musculoskeletal disorders, such as osteoarthritis (OA), an 
outcome criterion is recommended for each of these domains (e.g., for OA, a 0-10 numerical 
rating scale [NRS] for pain and the Western Ontario and MacMaster Universities 
Osteoarthritis Index [WOMAC] for functional impairment),(1-3). General outcome criteria, 
such as patient global assessment, are also recommended. 
In general, the results of clinical trials are reported at the group level, for example, with the 
mean change from baseline by treatment group or with the effect size. Because a statistically 
significant difference is mostly a matter of sample size and standard deviation of change in 
the variable, the most difficult issue is determining whether an observed difference is 
clinically important (4). How does a mean result at the group level (e.g., a mean change in 
pain of 1 point on a 0-10 point NRS) translate to a proportion of patients with clinically 
relevant improvement? To take into account the patient’s perspective and for easier 
interpretation of results, considering whether the change from baseline is important at the 
individual patient level and then reporting the percentage of patients with improved condition 
by treatment group is an interesting approach. 
This approach requires that for each patient, the continuous outcome measure (e.g., change in 
pain from baseline on a 0-10 NRS) be dichotomized into a binary variable (important change 
in pain from baseline, that is, change greater than a cut-off defining an important 
improvement in the patient’s perspective). Several cut-offs have been proposed to define the 
Minimal Clinically Important Difference (or Minimal Important Difference) (5, 6). Recently, 
the Minimum Clinically Important Improvement (MCII) (7) was proposed, because the 
 6 
amount of change patients consider clinically important is not the same with worsened or 
improved condition (8-10). Because only the patient can perceive whether the change in 
symptom is important, the definition of the MCII relies on an anchor-based method, with the 
patient’s opinion as the external anchor (6, 11, 12).  
The MCII reflects the concept of improvement (“feeling better”). The Patient Acceptable 
Symptomatic State (PASS) has been proposed to address the concept of partial symptomatic 
remission (“feeling good”) (13). These concepts are complementary: a patient’s condition can 
be markedly improved with treatment but can still be poor. For example, a score for pain that 
decreases from 9 to 5 on a 0-10 NRS is considered a success in terms of improved condition, 
but an absolute value of 5 still reflects a painful and/or disabling condition. Therefore, 
reporting the results of a trial in terms of both proportion of patients with improved condition 
and proportion in an acceptable state at the end of the trial is useful. The PASS value is a 
clinically relevant cut-off, from the patient’s perspective, that allows for classifying patients at 
the end of the trial as being in “an acceptable state” (i.e., with the outcome score ≤ the PASS) 
or not (i.e., with the outcome score > the PASS). The PASS was found more relevant than the 
MCII because the MCII is the amount of change needed to reach the PASS (14). However, 
when dichotomizing a continuous variable, reporting the between-groups difference in the 
proportion of patients with improved condition and the proportion in an acceptable state at the 
end of the trial is less powerful than reporting the effect size (15). Reporting both is 
considered an interesting approach (16-19).  
The concepts of MCII and PASS are supported by the Outcome Measures in Rheumatology 
international network (OMERACT), which has focused 2 meeting sessions (2004 and 2006) 
on this issue (19, 20) and has contributed importantly to understanding in this area. 
To date, MCII and PASS cut-off values have been estimated for hip and knee OA in France 
(7, 13) and acute painful shoulder in France (14). PASS values have been estimated for AS, 
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RA and psoriatic arthritis in Norway (21, 22); for RA in The Netherlands (23); and AS in the 
United States and Europe (24, 25) and Canada (26).  
This prospective multinational cohort study aimed to estimate the MCII and PASS for the 
main symptomatic criteria used in rheumatology, for 5 different diseases and in 7 different 
countries. 
 
Materials and methods  
Study design 
The Rheumatological Evaluation of Facts Leading to Excellent Treatment (REFLECT) study 
was a prospective, multicenter, multinational, observational, 4-week cohort study. 
Study population 
Patients were involved from hospital rheumatology department in Australia, Italy, Lebanon, 
Morocco, Spain and The Netherlands. To be included in the REFLECT study, outpatients had 
to be > 18 years old, experience pain from musculoskeletal disease ( 3 on a 0-10 NRS), 
having been prescribed a nonsteroidal anti-inflammatory drug (NSAID) for the next 4 weeks, 
and be able to understand the objectives of the study and complete questionnaires in the 
national language of the country where they live (i.e., English in Australia, French in France, 
Italian in Italy, Arabic in Lebanon and Morocco, Castillian in Spain, and Dutch in The 
Netherlands). This study involved patients with one of the following musculoskeletal 
diseases: RA as defined by the American College of Rheumatology (ACR) (27); AS as 
defined by the modified New York criteria (28), with a painful axial involvement at baseline; 
hand OA as defined by the ACR (29); hip and/or knee OA as defined by the ACR (30, 31); or 
mechanical back pain (BP) defined as back pain for at least 3 months resulting from a 
mechanical disorder.  
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Inclusion could begin with the start of a first NSAID or a switch from one NSAID to another. 
Patients were excluded if they had prosthesis on the assessed joint or if they had received an 
intra-articular injection in the 4 weeks before the study began. All patients initially visited the 
rheumatologist in charge of the patient, and an NSAID was prescribed (the drug and its 
dosage was chosen by the physician). A final visit to the same rheumatologist was scheduled 
4 weeks later.  
Data collection   
Data were collected at 2 visits (baseline visit and 4 week-follow-up). At the baseline visit, 
data were collected on demographics (age, gender, weight, height) and disease characteristics 
(date of symptom onset for each disease and specific characteristics for each evaluated 
disease).  
At both visits, patients assessed their status regarding their musculoskeletal disease by general 
and disease-specific patient-reported outcomes (PROs).  
- General PROs were 1) pain during the 48 hours before the visit, 2) patient global assessment 
of disease activity, and 3) functional disability. All these 3 outcomes were measured on a 0-10 
NRS. 
- Disease-specific PROs, according to each disease, were 1) Health Assessment Questionnaire 
(HAQ) score for RA (32), 2) Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 
(33) and Bath Ankylosing Spondylitis Functional Index (BASFI) (34) for AS, 3) 
Australian/Canadian Hand Osteoarthritis Index (35) for hand OA, 4) WOMAC (36) for hip or 
knee OA and 5) Roland and Morris questionnaire (37) for BP.  
At the baseline and final visits, the rheumatologist also rated global assessment of the disease 
activity (physician global assessment) on a 0-10 NRS (a general physician-reported outcome).  
In this article we report the results for the 4 general outcome measures: pain, patient global 
assessment of disease activity, functional disability and physician global assessment of 
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disease activity. Each of these generic outcomes was measured on a 0-10 NRS (appendix 1), 0 
being the best score and 10 the worst. For this report, all outcome scores were normalized to a 
0-100 score. 
A specific Case Report From (CRF) was available in each of the 6 languages involved. The 
questionnaires were translated to be as conceptually similar as possible by a single group with 
experience in translation and linguistic validation of patient questionnaires (see appendix 2).  
Outcome measures 
As previously described (7, 13), to determine the MCII and the PASS, we used an external 
anchoring method based on patient perspective. The external anchors, collected at the final 
visit, were as follows: for the MCII determination, the patients assessed the change from 
baseline on a 3-point Likert scale (improved, no change, or worse). If they reported an 
improvement, they were asked how important this improvement was to them (very important, 
moderately important, slightly important or not at all important).  
The MCII was estimated for both the absolute (final value – baseline value) and relative 
(
valuebaseline
valuebaselinevaluefinal 
) difference in each patient-reported outcome. The MCII was 
defined as the 75
th
 percentile of the distribution of change in PRO scores for patients who 
considered they had a slightly or moderately important improvement during the study (i.e., 
this change in symptoms [the MCII] or a lower change was achieved by 75% of patients with 
a slightly or moderately important improvement) (7). 
For the PASS determination, patients were asked “If you were to remain for the rest of your 
life as you were during the last 48 hours, would this be acceptable or unacceptable for you?” 
with a dichotomous response mode: acceptable or unacceptable. The PASS was defined as the 
75th percentile of the distribution of the PRO scores at the final visit for patients who 
considered their state acceptable at the end of the study (13).  
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The wording of the external anchors for determining the MCII and PASS in the different 
languages is given in the Appendix 2. 
 
Statistical analysis 
Analyses were conducted first by disease and then by country.  
Logistic regression was used to model the observations and compute MCII and PASS 
estimates (according to the 75
th
 percentile of the logistic curve, as described above) and their 
95% confidence intervals (95% CIs). Data for patients with missing data in one of the 
outcomes (general outcome measures or external anchor) were excluded from the analyses 
concerning this outcome.  
If the number of patients for which the MCII or the PASS had to be estimated was too low 
(<20), the cut-offs were not estimated for that subgroup. Data for patients lost to follow-up 
were excluded from the analysis. Statistical analysis involved use of SAS 8.2 (SAS Inst., 
Cary, NC) and Splus 6.2 (TIBCO Software Inc).  
Ethics 
This study was conducted in compliance with the Good Clinical Practices and Declaration of 
Helsinki principles. 
This study was an observational study and not a clinical trial. The conduct of the study did not 
interfere with the usual care of patients. If local law required it, the national principal 
investigator obtained Institutional Review Board approval of the protocol, as well as approval 
of all subsequent major changes.  
Each patient gave their signed informed consent to be in the study if local law required it. 
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Results  
A total of 1,532 patients were enrolled in the study. The number of patients by disease and 
country is in Table 1; 1,505 (98%) patients completed the final visit. 
Clinical and demographic data are in Table 2. In all, 668 (44.5%) reported a slightly or 
moderately important improvement, and 1,014 (67.4%) reported being in an acceptable state 
at the end of the study.  
Baseline scores on a 0-10 NRS varied between diseases. Patients with hip or knee OA had the 
highest scores and those with RA the lowest.  
Figures 1 and 2 show the estimates of MCII and PASS with their 95% CIs for the 4 general 
outcome measures. Numerical data are given in the supplemental files. 
MCII 
For pain in the whole sample, the MCII for absolute difference was -17 (95% CI -18, -15) and 
the MCII for relative difference was -21% (-24%, -19%).  
For patient global assessment in the whole sample, the MCII for absolute difference was -15 
(-16, -14) and the MCII for relative difference was -20% (-21%, -18%).  
For functional disability assessment in the whole sample, the MCII for absolute difference 
was -12 (-13, -11) and the MCII for relative difference was -15% (-18%, -13%).  
For physician global assessment in the whole sample, the MCII for absolute difference was -
14 (-15, -14) and the MCII for relative difference was -18% (-20%, -16%).  
PASS 
In the whole sample, the PASS was 42 (40, 44) for pain, 43 (41, 45) for patient global 
assessment, 43 (41, 44) for functional disability assessment, and 39 (37, 40) for physician 
global assessment.  
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Globally, the MCII and PASS estimates were consistent across diseases and across countries 
when the samples were sufficient. Australia, Lebanon, Morocco and The Netherlands often 
had extreme values and wide confidence intervals because of MCII and PASS estimation for 
small groups of patients.  
For each PRO, patients with RA, who had the lowest baseline scores, had the lowest PASS. 
Similarly, patients with hip or knee OA, who had the highest baseline scores, had the highest 
PASS.  
The proportion of patients with both change in score higher than the MCII and final score 
lower than the PASS for the outcome criteria was 44.6% for pain, 39.8% for patient global 
assessment, 37.9% for functional disability assessment, and 30.1% for physician global 
assessment.  
 
Discussion  
The importance of defining a minimal important improvement or an acceptable state to use in 
trials reporting is widely accepted (38, 39). This prospective multinational study allowed for 
estimating in the same cohort -- globally, by disease, and nationally -- the MCII and PASS 
values for 4 generic outcomes used in clinical trials of 5 chronic rheumatic diseases -- RA, 
AS, hand OA, hip and/or knee OA and chronic BP. Furthermore, this is the first determination 
of the MCII and PASS for hand OA and chronic BP.  
Our estimates of the MCII and PASS were similar across diseases and countries, whatever the 
outcome measure. Results that deviated from the overall findings could be related to low 
enrolment (with large 95% CIs). Few patients were involved in this estimation of the MCII 
and PASS from Australia and The Netherlands as compared with France, Italy and Spain. The 
consistency of the MCII and PASS estimates reinforces the robustness of these concepts and 
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allows for promoting the same estimates of the MCII and PASS, whatever the disease or 
country, in reporting the results of trials of any of the 5 rheumatic diseases. Indeed, we need 
to agree on a single value (for each criterion) that could be used for reporting in all trials. 
Previously, values chosen for MCII or PASS cut-offs, among a range of relevant MCII and 
PASS values, had a low impact on the difference in success rate between arms in a trial (i.e., 
the proportion of patients benefiting from treatment) (40). Thus, the slight differences 
observed across diseases would not result in a distortion of results. We recommend the use of 
values of MCII (15/100 for absolute improvement, 20% for relative improvement) and PASS 
(40/100) in reporting the results of trials using pain, patient global assessment, functional 
disability or physician global assessment as outcome criteria for any of the 5 involved 
rheumatic diseases (Table 3).  
Musculoskeletal conditions have a great impact on quality of life. Indeed, among patients with 
a wide range of chronic diseases, those with musculoskeletal diseases report the poorest levels 
of physical functioning and pain (41). The consistency of PASS estimates across diseases 
allows for using the proportion of patients achieving the PASS for any the 4 generic outcome 
measures to compare the burden of the different diseases. 
Only one study has investigated differences in PASS estimates across countries. This study 
involved a multinational controlled trial database of AS and compared the United States and 
different European countries. PASS estimates were higher for English-speaking than non-
English-speaking countries (25). We did not include enough English-speaking patients to 
investigate this issue, which may need further investigation.  
Our MCII estimates for global pain and patient global assessment are consistent with those 
from previous studies, ranging from -15 to -20, (7, 13, 25), and the PASS estimates in this 
study are slightly higher than that found in most studies, about 35 (7, 13, 25), but lower than 
that found in a Canadian study, about 50 (26). 
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For the 4 outcome measures, the PASS cut-off appears to be slightly higher for hip or knee 
OA than the other diseases. However, hip or knee OA patients had the highest scores for the 4 
outcome measures at baseline. This finding agrees with previous results showing that patients 
with a chronic disease and with the most severe symptoms would consider satisfactory a 
higher level of symptoms than would patients with few symptoms (14).  
The main strength of this study is that it is the first estimation of the MCII and PASS in the 
same cohort. The methodology used was the same for each disease (5 diseases) and each 
country (7 countries), with the same wording for the external anchor, treatment, follow-up 
duration, and outcome measures, which allows for comparisons across diseases and countries.  
One limitation of the study is that for each of the 4 outcome measures, we used a discrete 0-10 
NRS to measure the outcome and then standardized it into a continuous 0-100 scale. This 
method relies on the assumption that the transformation was valid in this context. Recent 
work suggests that transformed WOMAC VAS values are clinically acceptable 
approximations of native NRS values (42). Thus, for pain, for instance, the overall MCII 
value will be -17 if pain is measured on a 0-100 visual analog scale (VAS), but the individual-
level MCII will be -2 if pain is measured on a 0-10 NRS, because the NRS is a discrete 
variable.  Similarly, the PASS value for pain will be 42 with a 0-100 VAS and 4 with a 0-10 
NRS.  
Another limitation of the study is that it involved patients receiving NSAIDs. Whether similar 
MCII and PASS estimates would be obtained for patients receiving TNF blockers, for 
example, is an issue. Patients receiving NSAIDs and biotherapy may have different 
expectations for treatment efficacy, with a more ambitious goal for biologics, which may 
affect MCII and PASS estimates. PASS values have been previously estimated in a trial of 
ankylosis spondylitis patients comparing adalimumab to placebo (24). PASS values for 
patient global assessment were 29.5 (95% CI 20.0, 39,0) for the adalimumab group and 53.0 
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(32.0, 81.0) for the placebo group. Similar values were observed for total back pain. However, 
these data were from small samples (88 patients in the adalimumab group and 24 in the 
placebo group) and the large confidence intervals do not allow for concluding any difference 
between the 2 groups and compared to our results.  
This article reports the MCII and PASS estimates for the 4 generic outcome measures 
recommended for use in trials of rheumatic disorders. The MCII and PASS estimates for 
disease-specific PROs will be reported in further articles. The consistency of the MCII and 
PASS estimates for the generic outcome measures allows for using the same estimate across 
the 5 conditions studied. Addressing the individual level by describing the proportion of 
patients with an important improvement (as defined by the MCII) or achieving the PASS cut-
off provides additional meaningful information from clinical trials and longitudinal 
observation studies. This approach will aid in the interpretation of results, add useful 
information for daily practice (43), and provide information that is complementary to the 
conventional presentation of results at the group level (mean changes in scores). Reporting the 
proportion of patients achieving the MCII and the PASS aims at complementing, not 
replacing, information on the effect size, because the effect size remains a more powerful 
approach.  
 
ACKNOWLEDGEMENTS 
We acknowledge Gabriel Baron, Arthur Allignol and Blandine Pasquet for their technical 
help in statistical analysis and reporting, and Dr F Nacci and S Guiducci for their efforts in 
implementing the study in Italy. 
 
 
 
 16 
REFERENCES 
1. Altman R, Brandt K, Hochberg M, Moskowitz R, Bellamy N, Bloch DA, et al. Design and conduct 
of clinical trials in patients with osteoarthritis: recommendations from a task force of the Osteoarthritis 
Research Society. Results from a workshop. Osteoarthritis Cartilage. 1996;4(4):217-43. 
2. Bellamy N, Kirwan J, Boers M, Brooks P, Strand V, Tugwell P, et al. Recommendations for a core 
set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus 
development at OMERACT III. J Rheumatol. 1997;24(4):799-802. 
3. GREES. Recommendations for the registration of drugs used in the treatment of osteoarthritis. 
Group for the respect of ethics and excellence in science (GREES): osteoarthritis section. Ann Rheum Dis. 
1996;55(8):552-7. 
4. Wright JG. Interpreting health-related quality of life scores: the simple rule of seven may not be so 
simple. Med Care. 2003;41(5):597-8. 
5. Beaton DE, Boers M, Wells GA. Many faces of the minimal clinically important difference (MCID): 
a literature review and directions for future research. Curr Opin Rheumatol. 2002;14(2):109-14. 
6. Crosby RD, Kolotkin RL, Williams GR. Defining clinically meaningful change in health-related 
quality of life. J Clin Epidemiol. 2003;56(5):395-407. 
7. Tubach F, Ravaud P, Baron G, Falissard B, Logeart I, Bellamy N, et al. Evaluation of clinically 
relevant changes in patient-reported outcomes in knee and hip osteoarthritis: the Minimal Clinically 
Important Improvement. Ann Rheum Dis. 2005;64(1):29-33. 
8. Cella D, Hahn EA, Dineen K. Meaningful change in cancer-specific quality of life scores: 
differences between improvement and worsening. Qual Life Res. 2002;11(3):207-21. 
9. Guyatt GH, Jaeschke RJ. Reassessing quality-of-life instruments in the evaluation of new drugs. 
Pharmacoeconomics. 1997;12(6):621-6. 
10. Schwartz AL, Meek PM, Nail LM, Fargo J, Lundquist M, Donofrio M, et al. Measurement of 
fatigue. determining minimally important clinical differences. J Clin Epidemiol. 2002;55(3):239-44. 
 17 
11. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically 
important difference. Control Clin Trials. 1989;10(4):407-15. 
12. Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a 
disease-specific Quality of Life Questionnaire. J Clin Epidemiol. 1994;47(1):81-7. 
13. Tubach F, Ravaud P, Baron G, Falissard B, Logeart I, Bellamy N, et al. Evaluation of clinically 
relevant states in patient-reported outcomes in knee and hip osteoarthritis: the Patient Acceptable Symptom 
State. Ann Rheum  Dis. 2005;64.(1):34-7. 
14. Tubach F, Dougados M, Falissard B, Baron G, Logeart I, Ravaud P. Feeling good rather than feeling 
better matters more to patients. Arthritis Rheum. 2006;55(4):526-30. 
15. Cohen J. The cost of dichotomization. Applied Psychol Meas. 1983;7:249-53. 
16. Altman DG, Royston P. The cost of dichotomising continuous variables. Bmj. 2006;332(7549):1080. 
17. Brozek JL, Guyatt GH, Schunemann HJ. How a well-grounded minimal important difference can 
enhance transparency of labelling claims and improve interpretation of a patient reported outcome measure. 
Health Qual Life Outcomes. 2006;4:69. 
18. Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, et al. Core outcome 
measures for chronic pain clinical trials: IMMPACT recommendations. Pain. 2005;113(1-2):9-19. 
19. Tubach F, Ravaud P, Beaton D, Boers M, Bombardier C, Felson DT, et al. Minimal clinically 
important improvement and patient acceptable symptom state for subjective outcome measures in rheumatic 
disorders. J Rheumatol. 2007;34(5):1188-93. 
20. Tubach F, Wells GA, Ravaud P, Dougados M. Minimal clinically important difference, low disease 
activity state, and patient acceptable symptom state: methodological issues. J Rheumatol. 2005;32(10):2025-
9. 
21. Kvamme M, Kristiansen I, Lie E, Kvien T. Identification of cutpoints for acceptable health status 
and important improvement in patient-reported outcomes, in rheumatoid arthritis, psoriatic arthritis, and 
ankylosing spondylitis. J Rheumatol. 2009;37(1):26-31. 
 18 
22. Tubach F, Pham T, Skomsvoll JF, Mikkelsen K, Bjorneboe O, Ravaud P, et al. Stability of the 
patient acceptable symptomatic state over time in outcome criteria in ankylosing spondylitis. Arthritis 
Rheum. 2006;55(6):960-3. 
23. Ten Klooster PM, Drossaers-Bakker KW, Taal E, van de Laar MA. Patient-perceived satisfactory 
improvement (PPSI): interpreting meaningful change in pain from the patient's perspective. Pain. 
2006;121(1-2):151-7. 
24. Dougados M, Luo M, Maksymowych W, Chmiel J, Chen N, Wong R, et al. Evaluation of the patient 
acceptable symptom state as an outcome measure in patients with ankylosing spondylitis: data from a 
randomized controlled trial. Arthritis Rheum. 2008;59(4):553-60. 
25. Maksymowych W, Gooch K, Dougados M, Wong R, Chen N, Kupper H, et al. Thresholds of 
patient-reported outcomes that define the patient acceptable symptom state in ankylosing spondylitis vary 
over time and by treatment and patient characteristics. Arthritis Care Res. 2010;62(6):826-34. 
26. Maksymowych WP, Richardson R, Mallon C, van der Heijde D, Boonen A. Evaluation and 
validation of the patient acceptable symptom state (PASS) in patients with ankylosing spondylitis. Arthritis 
Rheum. 2007;57(1):133-9. 
27. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American 
Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 
1988;31(3):315-24. 
28. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing 
spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27(4):361-8. 
29. Altman R, Alarcon G, Appelrouth D, Bloch D, Borenstein D, Brandt K, et al. The American College 
of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand. Arthritis Rheum. 
1990;33(11):1601-10. 
 19 
30. Altman R, Alarcon G, Appelrouth D, Bloch D, Borenstein D, Brandt K, et al. The American College 
of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum. 
1991;34(5):505-14. 
31. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al. Development of criteria for the 
classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and 
Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum. 
1986;29(8):1039-49. 
32. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis 
Rheum. 1980;23(2):137-45. 
33. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining 
disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J 
Rheumatol. 1994;21(12):2286-91. 
34. Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to 
defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis 
Functional Index. J Rheumatol. 1994;21(12):2281-5. 
35. Kelli D A, Joanne M J, Jordan B R, Virginia B K. Validity, factor structure, and clinical relevance of 
the AUSCAN osteoarthritis hand index. Arthritis Rheum. 2006;54(2):551-6. 
36. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LWJ. Validation of WOMAC: A 
health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug 
therapy in patients with osteoarthitis of the hip or knee. J Rheumatol. 1995;15:1833-40. 
37. Roland M, Morris R. A study of the natural history of back pain. Part I: development of a reliable 
and sensitive measure of disability in low-back pain. Spine. 1983;8(2):141-4. 
38. Wells G, Anderson J, Beaton D, Bellamy N, Boers M, Bombardier C, et al. Minimal clinically 
important difference module: summary, recommendations, and research agenda. J Rheumatol. 
2001;28(2):452-4. 
 20 
39. Wells G, Boers M, Shea B, Anderson J, Felson D, Johnson K, et al. MCID/Low Disease Activity 
State Workshop: Low Disease Activity State in Rheumatoid Arthritis. J Rheumatol. 2003;30(5):1110-1. 
40. Tubach F, Giraudeau B, Ravaud P. The variability in MCII and PASS estimates did not have an 
impact on treatment effect estimates. J Clin Epidemiol. 2009;62(7):725-8. Epub 2009 Jan 6. 
41. Sprangers MA, de Regt EB, Andries F, van Agt HM, Bijl RV, de Boer JB, et al. Which chronic 
conditions are associated with better or poorer quality of life? J Clin Epidemiol. 2000;53(9):895-907. 
42. Bellamy N, Hendrikz J, Wilson C. Comparison of transformed visual analogue and native numerical 
rating scaled patient responses to the WOMAC Index. . Internal Medicine Journal 2011;41((Suppl.1)):23. 
43. Wells G, Anderson J, Boers M, Felson D, Heiberg T, Hewlett S, et al. MCID/Low Disease Activity 
State Workshop: Summary, Recommendations, and Research Agenda. J Rheumatol. 2003;30(5):1115-8. 
 
 21 
Table 1. Number of patients included in the study by disease and country. 
Countries Disease 
 AS BP Hand OA Hip/knee OA RA Total 
Australia  5 5 5 5 5 25 
France  95 106 102 109 101 513 
Italy  13 50 64 67 76 270 
Lebanon  40 0 0 44 41 125 
Morocco  33 50 0 50 30 163 
The Netherlands  15 0 0 0 23 38 
Spain  82 78 78 78 82 398 
TOTAL 283 289 249 353 358 1532 
 
* AS = ankylosing spondylitis; BP = back pain; OA = osteoarthritis; RA = rheumatoid 
arthritis 
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Table 2. Baseline characteristics of patients and changes from baseline in patient-reported outcomes. 
 AS 
(n=283) 
BP 
(n=289) 
Hand OA 
(n=249) 
Knee/Hip OA 
(n=353) 
RA 
(n=358) 
      
Male sex, no. (%) 214 (77) 87 (30) 30 (12) 66 (19) 62 (18) 
Age, years 43 ±14 56 ±15 64 ±11 65 ±12 54 ±15 
Body mass index, kg/m² 25 ± 4 27 ± 5 25 ± 4 29 ± 5 25 ± 5 
Disease duration, years 
median (IQR) 
13 ± 10 
11 (5-19) 
6 ± 8 
4 (1-8) 
7 ± 6 
5 (2-10) 
6 ± 6 
5 (2-9) 
10 ± 9 
6 (3-14) 
Pain (0-10 NRS)     
   Week 0  
        [median (IQR)] 
   Absolute change (week 0 - week 4) 
   Relative change (week 0 - week 4) 
 
60 ± 20 
[60 (50-70)] 
-20 ± 24 
-30 % ± 44% 
 
65 ± 18 
70 (50-80) 
-23 ± 23 
-34% ± 37% 
 
63 ± 17 
60 (50-80) 
-21 ± 23 
-31% ±33% 
 
67 ± 18 
70 (50-80) 
-22 ± 21 
-31% ± 33% 
 
59 ± 22 
60 (40-80) 
-18 ± 23 
-28% ± 39% 
Patient global assessment (0–10 NRS) 
   Week 0 
        [median (IQR)] 
   Change (week 0 - week 4) 
   Relative change (week 0 - week 4) 
 
60 ± 19 
[60 (50-70)] 
-17 ± 23 
-25 % ± 40% 
 
64 ± 17 
60 (50-80) 
-21 ± 22 
-30% ± 43% 
 
60 ± 18 
60 (50-70) 
-17 ± 20 
-26% ± 37% 
 
65 ± 18 
70 (50-80) 
-18 ± 20 
-24% ± 35% 
 
59 ± 19 
60 (50-70) 
-15 ± 21 
-22% ± 40% 
Physical function (0–10 NRS) 
   Week 0 
 
58 ± 22 
 
61 ± 20 
 
59 ± 19 
 
63 ± 19 
 
57 ± 21 
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        [median (IQR)] 
   Change (week 0-week 4) 
   Relative change (week 0 - week 4) 
[60 (40-70)] 
-16 ± 24 
-26 % ± 40% 
60 (50-70) 
-19 ± 22 
-30% ± 38% 
60 (50-70) 
-15 ± 22 
-22% ± 44% 
60 (50-80) 
-16 ± 21 
-20% ± 53% 
60 (40-70) 
-15 ± 21 
-23% ± 42% 
Physician global assessment (0–10 NRS) 
   Week 0  
        [median (IQR)] 
   Change (week 0 - week 4) 
   Relative change (week 0 - week 4) 
 
56 ± 18 
[60 (40-70)] 
-16 ± 20 
-27 % ± 36%  
 
56 ±15 
60 (40-70) 
-19 ± 20 
-33% ± 35% 
 
57 ± 16 
60 (50-70) 
-14 ± 17 
-24% ± 30% 
 
61 ± 16 
60 (50-70) 
-18 ± 16 
-29% ± 30% 
 
52 ± 18 
50 (40-70) 
-14 ± 17 
-24% ± 37% 
Patients reporting a slightly or moderately 
important improvement, no. (%) 
 
121 (44) 
 
123 (43) 
 
104 (43) 
 
169 (49) 
 
151 (43) 
Patients who considered their state at the 
end of the study acceptable, no. (%) 
 
178 (64) 
 
186 (65) 
 
182 (75) 
 
220 (64) 
 
248 (70) 
      
 
 
Values are mean ± SD unless otherwise indicated.  
AS = ankylosing spondylitis; BP = back pain; Hand OA = hand osteoarthritis; Knee/Hip OA = knee/hip osteoarthritis; RA = rheumatoid arthritis; 
NRS = numerical rating scale 
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Table 3. Recommended values for MCII and PASS for pain, patient global assessment, functional disability and physician global 
assessment. Important improvement in condition is defined as decrease in score higher than or equal to the MCII cut-off. Acceptable 
state is defined as a score strictly lower than the PASS cut-off. 
 
 Outcome measured on a 0-100 VAS* Outcome measured on a 0-10 NRS** 
MCII   
          MCII for absolute improvement 15/100 2/10 
          MCII for relative improvement 20% 20% 
   
PASS 40/100 4/10 
 
* VAS: visual analog scale 
** NRS: numerical rating scale 
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Figure 1: Estimates of the Minimum Clinically Important Improvement (MCII; absolute 
change and relative change) and 95% confidence intervals (95% CIs) for the 4 general 
outcome measures. Squares represent point estimates for each disease and each country. The 
overall MCII estimate (for the whole sample) with its 95% CI is at the bottom of the figure, 
represented as a larger square. Between brackets is the size of the sample for which the MCII 
was estimated. Australia and the Netherlands are not represented because of insufficient 
sample size for estimation. 
UCL: upper 95% confidence limit LCL: lower 95% confidence limit 
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Figure 2: Estimates of the Patient Acceptable Symptomatic State (PASS) with 95% CIs for 
the 4 general outcome measures. Squares represent point estimates for each disease and each 
country. The overall PASS estimate (for the whole sample) with its 95% CI is at the bottom of 
the figure, represented as a larger square. Between brackets is the size of the sample for which 
the PASS was estimated. Australia and the Netherlands are not represented because of 
insufficient sample size for estimation. 
UCL: upper 95% confidence limit LCL: lower 95% confidence limit 
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Appendix 1: 10-point numerical rating scale used to measure the 4 generic 
criteria 
 
Pain 
Circle the number that best describes the pain you felt due to your rheumatoid 
arthritis during the last 48 hours: 
 
0 1 2 3 4 5 6 7 8 9 10 
None Extreme 
 
Patient global assessment 
Considering all the ways your rheumatoid arthritis has affected you during the 
last 48 hours, circle the number that best describes how you have been doing 
 
0 1 2 3 4 5 6 7 8 9 10 
Very good Very bad 
 
Functional disability assessment 
Circle the number that best describes the difficulty you had in doing daily 
physical activities due to your rheumatoid arthritis during the last 48 hours. 
 
0 1 2 3 4 5 6 7 8 9 10 
None Extreme 
 
Physician global assessment 
Considering all the ways rheumatoid arthritis has affected your patient during 
the last 48 hours, circle the number that best describes how he/she has been 
doing:  
 
0 1 2 3 4 5 6 7 8 9 10 
Very good Very bad 
 
 30 
Appendix 2: Wording of the external anchors to determine the Minimal Clinically 
Important Improvement and the Patient Acceptable Symptomatic State estimates, in 
different languages. 
 
 Arabic:  
٤٨ةريخلأا ةعاس .  لا  تاريثأت عيمجب ركف(ضرملا مسا)  للاخ كيلع  
 
-١ 
 
 
 
 
 
 
 -٢ 
  
 
 
 
 
 
-٣ 
 
 
 
 
 
 
 
 
 
(ﻘﺘﻨا لاﺅﺴلا ﻰلا ل٣)  
(ﻘﺘﻨا لاﺅﺴلا ﻰلا ل٣)  
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 Castilian 
Piense en todas las formas en las que la (nombre de la enfermedad) le ha 
afectado durante las últimas 48 horas. 
 
1. En comparación con el momento de su incorporación al estudio, ¿cómo se 
ha encontrado en las últimas 48 horas? (Marque “X” sólo una de las casillas) 
 mejor 
 sin cambios (pase a la pregunta 3) 
 peor (pase a la pregunta 3) 
2. Si ha respondido “mejor” a la pregunta anterior, ¿qué importancia tiene 
para usted esta mejoría? (Marque “X” sólo una de las casillas) 
 mucha importancia 
 importancia moderada 
 importancia ligera 
 ninguna importancia 
3. Si tuviera que permanecer el resto de su vida tal y como ha estado las 
últimas 48 horas, ¿lo consideraría aceptable o inaceptable? (Marque “X” sólo 
una de las casillas) 
 aceptable 
 inaceptable 
 Dutch:  
Denk aan alle gevolgen van (naam van de ziekte) in de afgelopen 48 uur. 
 
1. Hoe ging het met u de afgelopen 48 uur in vergelijking met toen u aan de 
studie begon? (Zet hieronder in slechts één vakje een „ X ”) 
 beter  
 geen verandering (ga naar vraag 3) 
 slechter (ga naar vraag 3) 
2. Hoe belangrijk is deze verbetering voor u? 
(Zet hieronder in slechts één vakje een „ X ”) 
 heel belangrijk 
 tamelijk belangrijk 
 een beetje belangrijk 
 helemaal niet belangrijk 
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3. Als u voor de rest van uw leven zou moeten blijven zoals de afgelopen 48 
uur, zou dit dan aanvaardbaar of onaanvaardbaar voor u zijn? 
(Zet hieronder in slechts één vakje een „ X ”) 
 aanvaardbaar 
 onaanvaardbaar 
 English 
Think about all the ways your (disease name) has affected you during the last 
48 hours. 
 
1. Compared to when you started the study, how have you been during the 
last 48 hours? (Mark “X” in only one box below) 
 improved  
 no change (go to question 3) 
 worse (go to question 3) 
2. If you answer “improved” at the previous question, how important is this 
improvement to you? (Mark an “X” in only one box below) 
 very important 
 moderately important 
 slightly important 
 not at all important 
3. If you were to remain for the rest of your life as you were during the last 
48 hours, would this be acceptable or unacceptable for you? (Mark “X” in only 
one box below) 
 acceptable 
 unacceptable 
 French:  
Pensez à toutes les façons dont votre (nom de la maladie) vous a affecté(e) au 
cours des dernières 48 heures. 
 
1. Par rapport au début de l'étude, comment vous êtes-vous senti(e) au cours 
des dernières 48 heures  
 mieux 
 pas de changement (allez directement à la question 3) 
 moins bien (allez directement à la question 3) 
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2.     Si vous avez répondu « mieux » à la question précédente, quelle a été pour 
vous l’importance de cette amélioration ? (ne cocher qu’une seule case ) 
 Très importante  
 Modérément importante  
 Légèrement importante  
 Pas du tout importante 
3. Si vous deviez rester tout le reste de votre vie dans le même état que celui 
des dernières 48 heures, cela serait-il acceptable ou inacceptable pour 
vous ? (ne cocher qu’une seule case) 
 acceptable 
 inacceptable 
 Italian:  
Pensando a tutti i sintomi che (nome della malattia) le ha provocato nelle 
ultime 48 ore. 
 
1. Come si è sentito durante le ultime 48 ore rispetto a come si sentiva 
quando ha cominciato qiesto studio? (Barrare con una “X” solo una casella) 
 meglio  
 invariato (vada alla domanda 3) 
 peggio (vada alla domanda 3) 
2. Se ha risposto “meglio” alla domanda precedente, quanto è migliorata la 
sua condizione generale? (Barrare con una “X” solo una casella) 
 molto migliorata 
 moderatamente migliorata 
 migliorata di poco 
 migliorata quasi per niente 
3. Se la sintomatologia da lei presentata nelle ultime 48 ore, dovesse 
rimanere invariata per il resto della sua vita, sarebbe accettabile o 
inaccettabile per lei? (Barrare con una “X” solo una casella) 
 accettabile 
 inaccettabile 
 
